[Summary] A medical device enterprise dedicated to minimally invasive treatment
Hangzhou Qiming Medical Device Co., Ltd. was founded in 2009 and is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), dedicated to the research, development and industrialization of transcatheter treatment products for structural heart disease. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 10, 2019, with stock code 02500. Venus Medtech's full series of "Intelligent Manufacturing in China" valve products have entered more than 60 countries and regions worldwide, with footprints in Asia, Europe, South America and North America.
【Comprehensive Pipeline Leadership】
Currently, Venus Medtech has established a comprehensive overall solution for structural heart disease, covering heart valve diseases such as aortic valve, pulmonary valve, mitral valve and tricuspid valve, and also including hypertrophic cardiomyopathy, renal sympathetic denervation for hypertension, and surgical ancillary products, forming a complete pipeline.
The company has significant first-mover advantages in innovative product development. Its key products VenusA-Valve and VenusA-Plus are the world's first and second-generation TAVR products approved by NMPA and launched in China. VenusA-Valve is also the only product in China with up to 11 years of follow-up data. The company's international flagship product, the transcatheter pulmonary valve replacement (TPVR) system VenusP-Valve, has obtained EU CE MDR certification and has been approved for marketing by China's National Medical Products Administration (NMPA). It is the only self-expanding TPVR product approved for marketing in China and Europe; in 2023, it obtained Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA), becoming the only Chinese-made artificial heart valve approved by the FDA for clinical research.
The company's diversified product pipeline continues to achieve innovative breakthroughs, and multiple products have entered a new stage in mainstream global markets. The international multicenter clinical research protocol for the new-generation balloon-expandable dry valve Venus-Vitae SMART-ALIGN was grandly announced in 2023 at PCR London Valves, the top global event in the field of heart valve intervention. The new-generation fully deployable and fully recapturable dry valve product Venus-PowerX was approved for marketing in Argentina, successfully assisting multiple Latin American patients and bringing high-quality Chinese heart valve disease solutions to countries along the Belt and Road. The international multicenter clinical progress of the innovative transcatheter valve replacement system Cardiovalve is advancing rapidly, and its pivotal clinical study TARGET CE for tricuspid regurgitation covers dozens of renowned cardiovascular centers in Europe and North America.
【Strong R&D and Production Capabilities】
The company has a strong R&D and operations team, with a technical team composed of medical experts, valve and cardiac catheter research experts, and materials experts, achieving strong multidisciplinary integration. As of the end of April 2025, Venus Medtech had a total of 894 patents and patent applications, including 485 granted invention patents, with major countries and regions covered including China, the United States, Europe, Japan, Canada, Russia, India, Brazil, and others.
As a local innovative enterprise, Venus Medtech has won numerous awards and honors, including awards under the 12th Five-Year and 13th Five-Year National Science and Technology Support Programs assessed by the Ministry of Science and Technology of China, the second batch of national specialized and sophisticated "Little Giant" enterprises, the China Excellent Patent Award, Excellent Domestic Medical Equipment Products, and the National High-tech Enterprise title.
【Innovation-Led Development for the Future】
In the future, Venus Medtech will focus on new materials, bionics, image fusion technology and digital sensing, continuously updating and iterating and driving innovation to meet the vast needs of doctors and patients. As a leader in the heart valve field, the company hopes that the Venus Medtech model can provide a strong reference for the development of China's innovative medical industry. Innovation leads the future, and Venus Medtech will continue to be committed to the R&D and commercialization of innovative medical devices for structural heart disease, accelerating Chinese innovation and benefiting the world.
What does Hangzhou Qiming Medical Device Co., Ltd. require? Who is Venus Medtech hiring? Venus Medtech recruitment: 销售类占比最多占33%,其次是工厂生产类占19.8%. What education can get in at Venus Medtech? 本科占比最多占66%,其次是大专占18.9%. High education required at Venus Medtech? 硕士占12.3%. Work experience required at Venus Medtech? 不限占比最多占40.6%,其次是3-5年占25.5%. Where are the job locations at Venus Medtech? 杭州占比最多占66%,其次是北京占8.5%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows